real-time news and commentary for investors
Tuesday, Feb 26
United Therapeutics (UTHR +0.3%) holds on to gains in a weak tape after reporting Q4 earnings...
United Therapeutics (UTHR +0.3%) holds on to gains in a weak tape after reporting Q4 earnings that easily beat Street estimates this morning. Revenue increased across all product lines covering both chronic and life-threatening conditions. Gross margins declined to 84% from 87% however, largely due to inventory writedowns. The company reaffirms FY13 guidance bracketing estimates, expecting revenues to fall within a range of 5% above or below $1B. Analysts are looking for revenues of $993.85M.